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Drug shortage is a situation that affects the supply of medications, and in turn, 
affects hospitals, providers, and patients. When drugs are in short supply, patients may 
face treatment delays, may be unable to find essential drugs, or may face side effects 
from alternative agents, if alternatives are available. The problem of drug shortage is 
getting worse because the United States Food and Drug Administration, hospitals, and 
providers cannot anticipate future shortages. Left with no advanced strategies to face the 
problem of drug shortages, patient care can be negatively affected. This thesis was 
intended to answer three questions: 1) do the fluctuations in the number of suppliers prior 
to drug shortages has any effect on shortages of oncology drugs, 2) are there identifiable 
trends in number of suppliers and reasons for shortages that can be used to predict future 
shortages of oncology drugs, and 3) can variation in drug prices relative to shortages 
based on the number of suppliers in the market at any given time be used as a predictor of 
shortages? 
 The 41 injectable oncology drugs listed on The American Society of Health-
System Pharmacists, the University of Utah Drug Information Service, and Novation web 
site as in shortage between 2002 and 2010 served as the drugs of interest for this study.  
After excluding drugs that were available only as brand names as of 2011 (n=12 drugs), 




generic oncology drugs (n=24 drugs) was collected based on characteristics such as drug 
name, dosage form, route of administration, strength, quantity, price, manufacturer code, 
supplier name, and number of suppliers.  Only 17 products (18 dosage forms) were 
available for full analysis due to on-going shortages that extended beyond the data 
collection period. 
Study findings suggested that the volatility of some drug shortages is not in the 
number of suppliers prior to shortages; rather it is in the absence of the key manufacturer 
that is associated with the discontinuation of the brand name. The discontinuation of the 
brand names of the drugs was associated with a longer shortages period compared to 
shortages due manufacturing problems or delays. In reality, however five generic 
injectable manufacturers held the majority of the oncology packages and vials sold in the 
US market. Efforts should be directed at approving generic products from manufacturers 
committed to providing stability in the marketplace. Suppliers should have facilities and 
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The Food and Drug Administration (FDA) defines a drug shortage as “a  situation  
in which the total supply of all clinically interchangeable versions of an FDA-regulated 
drug is inadequate to meet the current or projected demand at the user level.”1 Drug 
shortages have an effect on the pharmacy department, healthcare providers, and patient 
care. When there is a drug shortage, the preparation and dispensing of medication by the 
pharmacy department is affected.2 In turn, patient care may also be affected because of 
potential delay of needed therapy as in the case of chemotherapy where a patient is on a 
specific chemotherapy regimen and one or more agents may be unavailable. 
Drug shortages are not new to the US healthcare system. A few shortages 
occurred during the mid 1990s, but national tracking began in 2001 when the Drug 
Product Shortages Management Resource Center was launched.3 The resource center 
represents collaboration between The American Society of Health-System Pharmacists 
(ASHP), Novation, and the University of Utah Drug Information Service (UUDIS). The 
UUDIS investigates reports of potential shortages. If shortages exist, the UUDIS will post 
this information on the ASHP Drug Product Shortages Management Resource Center and 
Novation website. 
From 2006 to present the number of drugs on short supply has tripled and through 






shortages in 2010 were sterile injectable drugs.5 Injectable drugs are more vulnerable to 
shortage because with their low- profit margin and complexity of the manufacturing 
process. Only a few companies may be interested in making generic injectable drugs. If a 
shortage occurs in these cases, it typically lasts months. Also, the majority of scarce 
drugs are generic, a situation almost never seen with brand name drugs. Therefore, 
generic drugs may not be economically attractive. Companies may have little incentive to 
keep up with production.4,6  
Reimbursement for injectable generic drugs is fixed by Medicare legislation at 
cost plus 6 percent above the average sale price.7 This fixed reimbursement scheme may 
discourage  generic  drug  production,  which  ultimately  limits  manufacturers’  and  
providers’  profitability.  This  may  also  discourage  providers,  especially  oncologists,  from  
prescribing generic drugs that already sell at a low profit margin.7 
Given a potential multitude of reasons why an injectable medication may end up 
on a shortage list, this thesis will examine oncology shortage data from 2002 to 2010 to 
identify a possible correlation between brand products leaving the market and drug 
shortages. This may be used to better predict shortages in advance and would allow better 
planning and potentially reduce impact on patient care outcomes.  
 
  




Causes of Drug Shortages 
 
Drug shortages are multifactorial in nature. A combination of factors can 
contribute to the shortage of a single drug and vice versa. Reasons behind a drug  
shortage may not always be known, because manufacturers are not required to disclose  
the reason. According to data from the UUDIS in 2010, 47 percent of drug shortages 
were due to unknown reasons, 28 percent due to manufacturing issues and 14 percent due 





Manufacturing processes of many drugs are complex, especially injectable drugs. 
Quality problems can occur at any step of production and may vary in intensity. 
Examples are a wrong expiration date on a package, microbial contamination of contents, 
impurities or crystallization due to stability changes. In 2010, 54 percent of the shortages 
of injectable drugs were due to quality issues according to the FDA.8   Another problem 
with injectable drugs is that many drugs are available in the form of lyophilized powder 
that needs to be reconstituted. Lack of lyophilized capability may also precipitate drug 






such as Vetter and Baxter planned to expand lyophilization capacity to keep up with 
future demand. For example, Vetter proposed increasing their lyophilization capacity to 
expand their annual production up to 24 million lyophilized units per year.9,10  
Good Manufacturing Practices (GMPs) are regulations enforced by the FDA to 
ensure that products meet quality standards throughout the manufacturing process and 
that final products are pure, safe, and effective. Pharmaceutical manufacturers who 
violate GMP regulations will be subjected to FDA form 483s, then warning letters, 
followed by consent decrees if multiple warnings do not result in change. If still not in 
compliance, manufacturers face product discontinuation, seize product, and finally plant 
closure by FDA.11  
Between 2006 and 2010, five major types of GMP violations accounted for 75 to 
85 percent of all FDA form 483s. In 2010 alone, there were 646 FDA form 483s.12 One 
of the most common violations is inadequate quality control and manufacturing 
validation. For example, in November 2011, Hospira received a new form 483 because its 
Texas plant had issues with quality control and training.13 As of 2011, Hospira was still 
not complying with GMP regulations at its North Carolina plant.13 Another common 
violation is lack of written documents of production and process control standard 
operating procedures. For example, in June 2011, Novel Laboratories, Inc., received a 
form 483 because written procedures for the cleaning and maintenance of equipment used 
in the processing or packing of a drug product were not established.14 
Finally, when a sole manufacturer does not comply with the GMPs, they are then 






have their own quality standards, and being unable to meet their own standards may 





Voluntary recalls can be a result of safety concerns such as harmful or defective 
product, noncompliance with regulations, or technical deficiencies such as deficiencies in 
labeling of drugs.2 This is especially problematic when one manufacturer dominates the 
supply. Voluntary recalls are usually temporary, affect specific lots, and are not subject to 
FDA legal actions. An example of a voluntary recall is that of Procrit ® (epoetin alfa) in 
late 2010.15 Procrit® is a growth factor used to treat anemia in patients with chronic 
kidney disease, anemia caused by zidovudine in HIV-infected patients and 
chemotherapy-induced anemia. The recall of the drug was due to the presence of 
lamellae, glass flakes, and protein clusters in glass vials of Procrit®. The recall of 
Procrit® led to a shortage not only of Procrit®, but also Aranesp® (darbepoetin alfa) the 
only other approved drug for chemotherapy-induced anemia. Because when one drug is 
recalled, the availability of the alternative may be affected. Also, stockpiling of the 





If the production of certain drugs, especially injectables, is complex and not 
economically attractive, some companies may decide to discontinue production. Another 
reason for drug discontinuation is low demand or safety issues that may force 






of permanent discontinuation of a drug due to safety concerns is the withdrawal of 
Vioxx® (rofecoxib) in 2004.17 Vioxx®, a cyclooxygenase type 2 inhibitor used to reduce 
pain and inflammation, was found to be associated with an increased risk of myocardial 
infarction and stroke among those who used it for more than 18 months. Safety concerns 
resulted in voluntary withdrawal and production discontinuation of the drug from the US 
and worldwide market.17 Another recent example of permanent discontinuation of a drug 
due to safety issues is the withdrawal of Xigris® (drotrecogin alfa) in October of 2011. 
Xigris® is used in adult patients with severe sepsis and sepsis shock to reduce the risk of 
mortality. It was withdrawn due to lack of efficacy and its failure to show survival 
benefits. Yet, neither the discontinuation of Vioxx or Xigris due to safety issues resulted 
in drug shortages.18 
Patent expiration and release of generic products can also have an impact on drug 
availability. Companies are granted exclusive rights to market new drugs for a specific 
time period as a way to recover the costs of research and development. When patent 
protection expires, other companies are allowed to compete and develop generic drugs. 
Generic drugs are usually cheaper to develop compared to brand-name drugs, because 
manufacturers of generic drugs do not have to go through the same processes as with the 
development of new drugs. Also, there are no research and development costs associated 
with the manufacturing of generic drugs. At the same time, generic drugs sell at cheaper 
prices compared to brand-name drugs. For that reason, it may be more economical for 
companies to discontinue drugs with low profit margins in order to concentrate on new 






Industry consolidation may also result in less competition and less investment in 
new drugs. A recent analysis of data on approximately 1,200 new drugs introduced and 
approved since 1950 showed that during the past 60 years, the number of new drug 
approvals was correlated with the number of pharmaceutical companies.20  Generic 
injectable drugs also have fewer manufacturers compared to other drugs. According to 
the IMS Institute for Healthcare Informatics (IMS IHI), two-thirds of all generic 
injectable drugs in short supply have three or fewer suppliers.  Also, data from IMS 
showed that in 2010, 80 percent of the packages and vials sold in the US market were 
held by the top five generic injectable manufacturers (Hospira Incorporated, Teva 
Pharmaceuticals, Boehringer Ingelheim (Bedford Labs), Fresenius Kabi (APP), and 
Novartis (Sandoz)), and that the top three manufacturers accounted for 71 percent of 
injectable drugs sold in the US market.21 
Finally, mergers may result in product discontinuation or delay product 
availability if the companies that have merged decided to move production lines to new 
facilities or narrow the focus of product lines.2 For example, in October 29, 2010, Baxter 
International Inc. divested its US generic injectables business to West-Ward 
Pharmaceuticals. Since then, West-Ward had discontinued production of some products 
such as metoclopramide (used to control nausea and vomiting).22 
Based on President Obama’s  2011 executive order to reduce prescription drug 
shortages, the FDA released a new interim rule in December of 2011. The new interim 
rule included a  more  specific  definition  of  the  term  “discontinuation”  to  include  not  only  
permanent discontinuation of medically necessary drugs, but also temporary 






as “any  interruption  of  manufacturing  of  a  drug  product”  more  specifically  “that  could  
lead to a potential disruption in supply of the drug product, whether the interruption is 
intended to be temporary or permanent.”23 According to this new rule, permanent 
discontinuation should be reported six months in advance, and temporary discontinuation 
should also be reported only if disruption in supply is anticipated.  
Product discontinuation is especially of concern because manufacturers are not 
obligated to report discontinuation of drugs to the FDA unless 1) it is considered a 
“medically necessary drug” and 2) if they are the sole manufacturer. FDA defines 
medically  necessary  as  any  drug  that  is  “used  to  prevent  or  treat  a  serious  or  life-
threatening disease or medical condition, for which there is no other available source with 
sufficient supply of that drug or alterative drug available.”24  Also, based on the FDA 
Interim Final rule, sole manufacturer was defined as  ‘‘an  applicant  that  is  the  only  entity  
currently manufacturing a drug product of a specific strength, dosage form, or route of 
administration for sale in the United States, whether the product is manufactured by the 
applicant or for the applicant under contract  with  one  or  more  different  entities.’’23  
Despite the presidential order and the Interim Final Rule, the FDA has no 
authority or influence on manufacturing capacity, and does not have the authority to 
impose penalties on manufacturing companies that do not report product discontinuation. 
Therefore, only a few companies have incentives to report product discontinuation even 
if they are the sole manufacturer. An example of sole manufacturer abrupt 
discontinuation of a drug without notifying the FDA is the discontinuation of ethiodized 
oil by Guerbet LL. Ethiodized oil is the only lipophilic nonionic iodinated contrast 






procedures for the treatment of primary and secondary hepatic malignancies. It is also 
labeled for use in patients undergoing lymphography, hysterosalpingography, and off-
label to detect hepatic metastases or for computed tomography of the liver and spleen. 




Supply-Demand Imbalances  
 
Ideally, when demand for a certain drug is equal to the supply, we are in a 
balanced situation. In many cases, demand can exceed supply such as in disease 
outbreaks, new unlabeled uses of drugs, or when a new therapeutic guideline is released, 
all leading to supply issues.2 The transition from one product formulation to another may 
also disrupt the supply of drugs and result in temporary shortages. For example, the 
change from a beef protein to plant protein source may delay drug production. 
Another theory to consider was stated by the Office of the Assistant Secretary for 
Planning and Evaluation (ASPE), US Department of Health and Human Services in a 
published analysis showing that supply and demand rules may not always work with 
medications because even with high prices, demand might remain the same.29 Given that, 
supply and demand rules may not apply as a cause of drug shortages.  
Limited  manufacturers’  capacity  may  also worsen the situation. Because multiple 
products may be produced in the same manufacturing line, increasing production of one 
drug as a result of high demand may automatically result in decrease production of 








Raw Material Shortages 
 
Raw materials shortages can result from environmental conditions such as 
climate, conflicts that may affect trade policies, natural disasters such as floods, fires, 
hurricanes and tornadoes, or damage during harvest, storage, and transportation.  Since 
80 percent of raw materials come from outside the US, 2 changes in trade policies or 
problems during production and transportation such as contamination may easily affect 
the whole US healthcare system. For example, heparin is produced by two companies; 
Baxter International and APP Pharmaceuticals. In 2008, FDA discovered that heparin 
produced by Baxter was contaminated by Chinese suppliers. Since the only other 
company that produces heparin was APP, FDA turned to APP for assistance. The 
dilemma however was that the  source  of  APP’s  product  was  also  China.31 
Raw material unavailability may also be due to manufacturers’ relocation of their 
facilities, such as the case of kanamycin sulfate injection shortage. As of September 
2011, kanamycin sulfate injection had been on short supply since February 2009 because 
the manufacturer, APP, had been unable to obtain raw materials from the supplier, USP, 
who was relocating its facilities. Shortages due to raw material unavailability can be 




The  “Gray Market”  
 
The majority of health systems, hospitals, pharmacies, and physician practices 
obtain their drug supplies from traditional distributors such as wholesale distributors or 






authorized from the manufacturers. Gray market vendors can be a source of frustration 
during a shortage, because they buy excessive quantities of certain drugs and then resell 
them at high markups.  
Between July and August of 2011, the Institute for Safe Medication Practices 
(ISMP) conducted a survey on gray market usage and drug shortages.34 In the survey, 
pharmacists and purchasing agents at 549 hospitals across the nation were asked about 
their experiences with drug shortages. Results showed that 56 percent of respondents 
reported they have been contacted on a daily basis by up to 10 different gray market 
vendors. Additionally, 35 percent of community hospitals reported price markups that 
were 10 times or more than the regular price.34 For example, the survey found that the 
markup for Cytarabine, an antineoplastic agent used to treat acute nonlymphocytic 
leukemia, acute lymphocytic leukemia and in the prophylaxis and treatment of meningeal 
leukemia, was as high as 3,980 percent.35 To know whether gray market distributors are 
contributing to the problem or not, it is important to determine how distributors find out 
about shortages and from where they buy the drugs in short supply.  
  
 
End-User Stockpiling  
 
Finally, end-users may exacerbate the problem of drug shortages if they start 
stockpiling as an attempt to protect themselves from any possible shortage. Stockpiling 
occurs when end-users place orders that are far more than their normal requirement, 
resulting in instability of the drug supply chain.36 In June 2011, the American Hospital 
Association (AHA) surveyed community hospital chief executive officers from 820 






Survey results indicated that 85 percent of hospitals had purchased excess drug inventory 
in order to make sure they are ready in case of shortages.37  
 
 
Publicly Available Information on Drug Shortages 
 
Information about drug shortages can be obtained from different sources. FDA, 
ASHP, Centers for Diseases Control and Prevention (CDC), and manufacturing 
companies themselves are all publicly available information sources. The FDA and 
ASHP websites are the most comprehensive sources, although they provide slightly 
different information. The ASHP website tracks all prescription drugs that are in short 
supply, including manufacturers’  names,  reasons for the shortage, estimated resupply 
dates, and implications for patient care. FDA website, on the other hand, mainly focuses 
on  drugs  believed  to  be  “medically  necessary.”2 CDC’s  primary  focus  is  on  vaccine  
shortages, and obtaining vaccine information from drug companies is sometimes 
challenging. 
As previously described, companies are not obligated to report manufacturing 
problems or product discontinuation to the FDA. Therefore, abrupt shortages can occur 
with no advance strategy to help hospitals, pharmacies, providers, or patients cope with 
either the problem or planning for drug shortages.  
 
 
Broadening Public Interest in Drug Shortages 
 
In July 9, 2012, the Food and Drug Administration Safety and Innovation Act 
(FDASIA) were signed into law. This bill, mandated that the FDA track all drugs that are 
prone to shortages, 2) all drug companies to notify the FDA about manufacturing 






projected to begin, and 3) manufacturers report product discontinuation either it is 
temporary or permanently.38  
Other public recognition of the problem of drug shortages comes from Rep. Elijah 
E. Cummings’ investigation into drug shortages and gray market practices. On October 5, 
2011, Rep. Cummings, the ranking Democrat on the House Oversight and Government 
Reform Committee, sent a request to five distributors (Allied Medical Supply Inc., 
Superior Medical Supply Inc., Premium Health Services Inc., PRN Pharmaceuticals, and 
Reliance Wholesale, Inc.) to provide detailed information on sources of drugs in short 
supply that they are buying and selling to hospitals. He also asked for an accounting of 
their profits from selling them. One of the letters was sent to Allied Medical Supply, Inc., 
to get  answers  on  the  company’s  sales  and  sources  of  cytarabine.  The usual price of 
cytarabine was $12 per vials, but Allied Medical Supply was selling it for approximately 
$990.26 Having to pay more than 80 times the typical sale price for a certain drug may 
also lead to direct or indirect costs such as paying more for the drug in short supply or 
added labor to manage and find alternatives.39  
As previously described, President Obama released an executive order in 2011 in 
an effort to reduce prescription drug shortages. The order directed the FDA to take the 
steps necessary to reduce and prevent shortages of lifesaving medications, to expedite 
regulatory review as much as possible, and to communicate with the Department of 
Justice (DOJ) any finding related to drugs being sold at very high markups.40 The 
previously mentioned efforts show that the problem of drug shortages is on government 







Impact of Drug Shortages  
 
Drug shortages may raise some safety concerns such as adverse effects on patients 
or medication errors, especially when using medications purchased from unknown 
sources. When familiar drugs are in short supply, physicians have to choose alternative 
medications if available, and clinicians’  unfamiliarity with alternative medications may 
risk  patients’  safety.  For  example,  an  assessment  done between January 1, 2001, and June 
30, 2002 in the University of Utah Hospitals and Clinics (UUHC) showed  that  clinicians’  
unfamiliarity with alternative medications in term of dosage requirement was the most 
common source of safety problems.41  
 
 
Medication Errors    
 
A medication error is defined as “any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in the control of the 
healthcare professional, patient, or consumer. Such events may be related to professional 
practice, healthcare products, procedures, and systems, including prescribing; order 
communication, product labeling, packaging, and nomenclature; compounding; 
dispensing; distribution; administration; education; monitoring; and use.”42 On the other 
hand, near-miss errors or a close  call  is  defined  as  “an  event,  situation,  or  error  that  took  
place but was captured before reaching the patient.”  43The 2011 ISMP survey showed 
that due to drug shortages, one in four of the 1,800 healthcare practitioners they surveyed 







Most of the errors mentioned in the ISMP survey were reportedly due to shortages 
of high-alert medications. High-alert medications typically have a low margin of safety 
and a high risk of causing harm when misused. Examples of high-alert medications are 
heparin, morphine, and propofol. The ISMP survey also mentioned that errors were 
common due to shortages of cancer drugs such as etoposide. Etoposide is used in 
combination with other chemotherapeutic agents to treat many cancers such as small cell 
lung cancer, refractory testicular tumors, lymphomas, leukemias, and brain tumors. When 
IV etoposide was unavailable, providers switched to oral etoposide.  Because not many 
providers knew that oral dose of etoposide needed to be double the IV dose, near-miss 
errors occurred. Also, when leucovorin, used in combination with 5-fluorouracil in 
patients with advanced colorectal cancer, was in short supply, some patients were instead 
prescribed capecitabine, used to treat breast and colorectal cancer, which resulted in 
serious gastrointestinal toxicity. Other patients were prescribed wrong doses of 
levoleucovorin, the levo isomeric form of racemic leucovorin, of which the impact on 
quality of life or overall survival was undetermined.44 
 
 
Adverse Outcomes  
 
The 2011 AHA survey showed that 35 percent of hospitals reported that patients 
experienced adverse outcomes as a result of drug shortages. In other words, one in five 
patients treated experienced adverse outcomes. This could be an underestimation of the 
magnitude of the problem because only 820 hospitals were included in the survey. 









 Finally, drug shortages can result in suboptimal treatment, delay of treatment, or 
no treatment at all. The 2011 AHA survey showed that due to drug shortages, 82 percent 
of the 820 participants reportedly  delayed  patients’  treatment,  and  69 percent reportedly 
provided patients with less effective drugs.37 
 
 
Problems with Alternative Agents 
 
When switching from one agent to an alternative agent, many issues may arise. 
First, the alternative agent may have a lower risk profile and/or superior efficacy that 
require dosage adjustments. For example, three patients were given IV hydromorphone at 
the intended dose for morphine, which resulted in the death of two patients and increased 
length of hospitalization of the third patient.44 
Second, alternative agents may be of different dosage form. Many errors have 
been experienced by providers and patients due to dosage form differences between the 
standard of care medication and alternative agents. When propofol was in short supply, 
Precedex® (dexmedetomidine) was used instead. The dosing of Precedex® is in 
mcg/kg/hour, but physicians’ unfamiliarity with the new agent resulted in errors due to 
dosing it in mcg/kg/minute as with propofol. Also, pharmacists may experience problems 
with dosing as well. When pre-diluted methotrexate was unavailable, a vial of dry 
powder had to be reconstituted, and some vials were incorrectly diluted, resulting in a 
less than effective dose of methotrexate being provided to a patient.44 
Third, problems with alternative agents of questionable quality are especially 






in the gray market may be stolen, mislabeled, or stored in unknown conditions. The 
August 2011 ISMP survey on gray market usage showed that approximately 12 percent 
of the 549 hospitals they included in the survey reported adverse events and errors from 
the improper storage and counterfeit drugs sold in the gray market.34 
Fourth, the supply of effective alternative agents may be affected as well due to 
increased demand, which may in turn worsen the shortage situation or further delay 
treatment. Or in worst cases, hospitals may be encouraged to either stockpile or ration 
care. For example, when morphine was in short supply, increased demand on the 
alternative, hydromorphone, resulted in both drugs being included in the list of drugs on 
short supply.44 
A fifth problem is simply the unavailability of an alternative such as treatment for 
patients with pseudomonas infection who are only sensitive to amikacin. The 
unavailability of that drug resulted in patients hospitalized due to treatment failures, and 
in some cases, patients died.44 
 
 
Chemotherapy Drug Shortages 
 
Shortage of chemotherapy drugs is a growing problem that affects providers and 
threatens patient care. In 2010 alone, there were 23 cancer drugs on shortage, some of 
which included cytarabine, cisplatin, doxorubicin, leucovorin, etoposide, paclitaxel, 
vinblastine, and busulfan.5 According to the AHA survey, in the first six months of 2011, 
99.5 percent of U.S hospitals experienced one or more drug shortages. And, 44 percent of 






shortages, 66 percent experienced chemotherapy drug shortages, and nearly 47 percent of 
hospitals had to deal with shortages on a daily basis.37 
Shortages of chemotherapeutic agents are of great concern, because a significant 
number of the drugs in short supply are part of the oncology standard of care. Oncology 
“standard  of  care”  is  usually  a  combination  of  three to four drugs (chemo cocktail) with 
different mechanisms of action in order to limit the chances of cancer cells to mutate and 
become resistant, as may be experienced with single agent. A shortage of one single drug 
may cause delays in treatment and dosing of drugs, or result in the use of less effective 
alternatives or alternatives with more side effects. Also, not treating the cancer in a timely 
manner or with the established standard of chemotherapy combination therapies may 
increase the likelihood of metastasis of the primary cancer to other parts of the body.  
Another concern with chemotherapy drug shortages is people fear that shortages 
may impact their survival, leading to a feeling of helplessness and anxiety. Also, many 
patients rely on clinical trials to access treatment, and shortage of the old cancer drugs 
will force some trials to stop or change protocols, a step that has a negative effect on the 
quality of care provided and the results of the trial itself.4,6  Pediatric oncology could also 
be affected by drug shortages. Many of the therapies used in children with cancer have 
few or no acceptable alternatives and lack evidence-base for substitutions, making it even 
harder for children to stand shortages.6 
Finally, only a few companies manufacture cancer drugs. If one or two companies 
face a production problem or have to stop the supply of raw materials or specific parts 
required for the production process, other companies may be unable to meet the demand, 






leukemia with no known substitute, is a product of companies such as Hospira, APP 
Pharmaceuticals, and Bedford Laboratories. In 2010, Hospira and APP found crystals in 
some of the vials and had to stop production and shipment of the drug. Bedford 
Laboratories, on the other hand, faced a huge demand that exceeded its supply capacity.5 
Since then, cytarabine has been in short supply because of Bedford production delays. In 
November 19, 2011, Ben Venue Laboratories, the manufacturing arm of Bedford 
Laboratories, voluntarily and temporarily decided to suspended manufacturing and 
distribution of products manufactured in its Bedford, OH facility.45 This further delays 
production and worsens the shortage problem. 
With chemotherapy drug shortages, there is also a risk of rationing care, a 
challenging situation to both providers and patients. According to the AHA survey of 
hospitals relative to drug shortages, 78 percent of hospitals have rationed care for drugs 
in short supply; almost three out of four hospitals implemented restrictions on drug use 
for specific patients.37 Hospitals can also reserve drugs for desperately needed patients or 
patients on critical care and exclude new patients. For example, Doxil® (doxorubicin 
liposomal), a drug used to treat advanced ovarian cancers, was in short supply. Janssen 
Products, LP the sole supplier of doxorubicin liposomal, rationed this product and 
assigned it only to specific patients. They posted a letter on its website that included 
information on the shortage of the drug and advised healthcare providers not to start the 
drug with new patients without any information on who is to use it and who not.46   
 
 
Drug Shortages and Cost  
 
Drug shortages are also sometimes blamed for driving up healthcare costs.37 Cost 






related to drug prices. For example, many hospitals have to buy drugs at high markups 
from the gray market in order to continue providing care for their patients.  According to 
the August 2011 report by Premier Healthcare Alliance, the average markup of drugs sold 
in the gray market was 650 percent.47 For that, the cost of drugs from the gray market is 
10 to 1,000 times the usual cost. Therefore, the economic burden on hospitals is estimated 
to be approximately $200 million annually, and healthcare providers are paying 11 
percent more for those drugs on shortages.48 
“Indirect costs”  are related to the added labor to find alternatives to drugs on short 
supply and to manage shortages as well as time spent by providers themselves to manage 
drug shortages. It is estimated that the annual labor costs associated with managing drug 
shortages for all health systems nationwide in 2010 were approximately $216 million. 
And, the median time spent by pharmacists and pharmacy technicians to manage 
shortages were eight to nine hours per week.49 
Finally, “Intangible” costs are those related to the anxiety and stress patients and 
providers have to go through to manage shortages and find alternatives. “Intangible”  
costs are hard to quantify because the patients and providers affected may have different 
perspectives and may be affected differently.  Chemotherapy drug shortages have not 
only affected patients’ stress and anxiety, but also have an effect on chemotherapeutic 
drugs costs. Yet, the  change  in  chemotherapeutic  agents’  costs  due to shortages is not 
well known. Have the shortages of chemotherapeutic agents increased, decreased, or had 
no effect on the costs and prices of cancer drugs?  
The only study that looked at the effect of drug shortages on drug prices was 






US Department of Health and Human Services in 2011.29 The ASPE study examined the 
factors that led to prescription drug shortages, and then looked at the impact that 
shortages had on pricing for oncology drugs in particular. In short, Medicare Part B data 
were evaluated to review the change in volume of services and change in prices of 
injectable drugs between the period of 2006 and 2008 where no drug shortages were 
reported and between the period of 2008 and 2011 where drug shortages were reported. 
The analysis showed that the average price of drugs that experienced shortages in supply 
decreased in the years before shortages started, resulting in drug shortages. The study was 
homogenous since it used only Medicare Part B data, and it was performed at the national 
level using Medicare Part B data. Also, the ASPE study tracked the change in prices only 
from 2008 to 2011 regardless of the number of suppliers.  Therefore, a major unknown is 
still whether 1) shortages are due, in part, to the number of suppliers for a product, and 2) 
whether there is some optimal number of suppliers that would be required in order to 
avoid drug shortages. 
The only other study that looked at the relationship between the number of drug 
suppliers and the volatility of drug shortages was the study done by the IMS IHI in 
2011.21 The study looked at all injectable and oral drugs that had been reported in 
national shortages as of October 7 2011. One of their findings was that drugs that 
supplied by three or fewer companies are at the highest risk of being in shortages. The 
IMS IHI findings help in the way we look at drug shortages from a supply perspective.  
But at what point are drugs more prone to become listed as part of a shortage? Is it one 
supplier, two suppliers, or three suppliers? Can we figure out a trend between the number 






occur, is there any relationship to price, i.e., too low a price will encourage producers to 





Given the unknown of whether changes in the number of suppliers actually have 
an impact on drug shortages in the US, three primary questions will be studied. First, 
whether the number of suppliers prior to shortages has any effect on the shortages of 
oncology drugs will be analyzed. Second, whether identifiable trends can be used to 
predict future shortages. Third, based on the number of suppliers in the market at any 
given time during the time period 2002-2010, variation in drug prices relative to 






      The purpose of this thesis is to assess whether during the time period 2002-2010  
1) fluctuations in the number of suppliers prior to drug shortages have any effect on 
shortages of oncology drugs, 
2) identifiable trends in number of suppliers and reasons for shortages can be used to 
predict future shortages of oncology drugs, and 
3) variation in drug prices relative to shortages based on the number of suppliers in 
the market at any given time can be used as a predictor of shortages   
 
 
Data Collection Methods 
 
For  the  purposes  of  this  study,  a  “drug  shortage”  will  be  defined  as  “an  inadequate  
supply  of  any  injectable  oncology  drug  between  2002  and  2010.”    The  41  injectable  
oncology drugs that were listed on the ASHP/UU DIS/Novation web site as in shortage 
between 2002 and 2010 served as the drugs of interest for this study.  After excluding 
drugs that were only available as brand names as of 2011 (n=12 drugs) and drugs that 
have been in short supply after 2010 (n=5), information on the remaining generic 
oncology drugs (n=24 drugs) will be collected based on characteristics defined in Table 
1.  Drug name, generic and brand if available, dosage form, route of administration, 






Table 1: Characteristics of injectable oncology drugs 
Variable  Description Source of Variable  
Drug Name Generic name 
Brand name 




Food and Drug 
Administration (FDA) 
 
The Red Book 
 
Supplier Name  
Number of Suppliers   
Dosage Form  Solution (SOL) 
Powder for Solution (PDS) 
Route of Administration  Intravenous (IV) 
Injection (IJ) 
Strength   
Quantity   
Price  Average Wholesale Price 
(AWP) 
Manufacturer Code  National Drug Code (NDC) 






University of Utah Drug  
Information Service 
(UUDIS) 
Shortage Time Frame x months in shortage 
Reasons for Shortages  Business Decision (BD) 
Discontinued (D) 
Manufacturing delays (MD) 
Manufacturing Problems 
(MP) 
Raw material (RM) 
Regulatory Problems (RP) 
















be collected from three different sources; UUDIS, FDA, and The Red Book. The Average 
Wholesale Price from the Red Book is updated on a yearly basis. Shortage information, 
length of shortages, and reasons for shortages will be collected from the UUDIS. Reasons 
for shortages are predefined reasons according to UUDIS recordkeeping. The 24 
oncology drugs of interest for this study are listed in Table 2.  Data collection tables such 
as Table 3 will be used to categorize and record data for each of the injectable oncology 





Descriptive statistics will be used to assess the mean change in number of 
suppliers prior to drug shortages, mean number of suppliers during shortages to predict 
future shortages, and mean annual change in price based on the annual Average 
Wholesale Price (AWP) listed in the Red Book.  Reasons for shortages will be quantified 






















Dacarbazine Mitomycin  
Daunorubicin Hydrochloride  Mitoxantrone 
Doxorubicin Hydrochloride Paclitaxel 
Epirubicin Hydrochloride Pentostatin 
Etoposide Thiotepa  
Fludarabine Vinblastine 
Fluorouracil  Vincristine  
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Table 3: Sample data collection form for Drug x 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Shortage in year (X = yes)          
Length of shortage (days)          
Reason(s) for shortages          
Supplier 
Name 






















Supplier 1            
Supplier 2            
Supplier 3            
Supplier 4            









Supplier Fluctuation Trends as a Shortage Predictor 
 
After data were collected for each of the 24 oncology drugs of interest, the total 
number of companies in each year as well as the total number of distinctive companies 
throughout the study period were counted. Table 4 shows the number of companies for 
each of the 24 injectable generic multisource oncology drugs of interest (2002-2010) and 
the total number of distinctive companies during the same period.  
Table 5 lists descriptive statistics relative to the number of manufacturers for each 
oncology drug that was in short supply during the studied period. Evaluation shows that 
the majority of drugs had a median number of less than five producers during any given 
year. Ten drugs were available from four or more producers, of which only mesna and 
doxorubicin were still available from the brand name manufacturer (20 percent).  Eleven 
drugs were available from three producers or less, of which only three were still available 
from brand name manufacturers (27.2 percent).  Finally, three products were only 
available from one producer, two of which were only available as the brand name (66.7 
percent).  Analysis appears to support the premise that as brand name manufacturers step 
out of the market and generic producers increase in number, volatility in availability is 
introduced. 





Number of companies for the 24 injectable generic oncology drugs of interest (2002-2010) 
 





Bleomycin 3 4 4 5 4 4 4 5 4 6 2007 
Carboplatin 1 1 1 5 8 11 9 9 7 12 Brand 
discontinued 
prior to shortages 
Cisplatin 5 5 5 5 5 4 4 3 3 5 2005 
Cyclophosphamide 2 2 2 2 2 2 2 2 2 3 2008 
Cytarabine 5 4 3 4 4 4 5 5 5 6 Brand 
discontinued 
prior to shortages 
Dacarbazine 4 5 5 5 5 5 5 5 5 5 Brand 
discontinued 
prior to shortages 
Daunorubicin 
Hydrochloride  
2 2 3 3 3 3 3 3 3 3 Available 
Doxorubicin 
Hydrochloride 
5 2 4 4 4 4 5 4 4 7 Available 
Epirubicin 
Hydrochloride 
1 1 1 1 1 2 9 7 7 9 Available 
Etoposide 6 6 5 5 5 4 4 4 4 6 2010 
Fludarabine 1 1 2 2 2 2 4 5 6 7 Available 
Fluorouracil  4 3 3 3 3 3 4 4 4 7 2003 
Idarubicin 1 2 2 2 2 2 4 4 5 6 Available 
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Ifosfamide 1 2 2 2 3 3 4 4 3 4 Available 
Leucovorin 6 3 2 4 3 2 2 2 2 6 Unknown 
Mesna 2 3 3 5 5 5 5 5 4 5 Available 
Methotrexate 6 3 3 3 3 3 4 4 5 8 Unknown 
Mitomycin  5 4 4 4 4 4 2 2 3 6 2007 
Mitoxantrone 1 1 1 1 1 5 7 7 7 7 2011 
Paclitaxel 4 5 5 6 6 5 7 8 6 10 2009 
Pentostatin 1 1 1 1 1 1 2 2 2 3 Available 
Thiotepa  3 3 3 2 2 2 2 2 2 3 2004  
Vinblastine 3 3 2 2 2 2 2 2 2 3 Brand 
discontinued 
prior to shortages 
Vincristine  3 3 2 2 2 2 2 2 2 3 Brand 
discontinued 
prior to shortages 
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Table 5: Mean and median number of suppliers for the 24 injectable generic oncology 
drugs of interest (2002-2010) 
 
Drug Name Mean Median Range  
Carboplatin 5.7 7 1-11 
Paclitaxel 5.7 6 4-8 
Cisplatin 4.3 5 3-5 
Dacarbazine 4.8 5 4-5 
Etoposide 4.7 5 4-6 
Mesna* 4.1 5 2-5 
Bleomycin 4.1 4 3-5 
Cytarabine 4.3 4 3-5 
Doxorubicin Hydrochloride* 4.0 4 2-5 
Mitomycin  3.5 4 2-5 
Daunorubicin Hydrochloride*  2.7 3 2-3 
Fluorouracil  3.4 3 3-4 
Ifosfamide* 2.6 3 1-4 
Methotrexate 3.7 3 3-6 
Cyclophosphamide 2.0 2 2 
Fludarabine* 2.7 2 1-6 
Idarubicin* 2.6 2 1-5 
Leucovorin 2.8 2 2-6 
Thiotepa  2.2 2 2-3 
Vinblastine 2.2 2 2-3 
Vincristine  2.2 2 2-3 
Epirubicin Hydrochloride* 3.3 1 1-9 
Mitoxantrone 3.4 1 1-7 
Pentostatin* 1.3 1 1-2 












Table 6 shows the trend in number of suppliers and reasons for shortages of the 
24 original study drugs of interest (2001-2010), ongoing shortages of injectable generic 
oncology drugs that started prior to December 2010, as well as the shortages of those 
drugs that started after December 2010 (the studied period). Study drugs have been 
ordered from most to least total number of months of shortage from 2002 to 2010. The 
majority of shortages of injectable generic oncology drugs of interest (2002-2010) were 
due to unknown reasons (14/24, 58.3 percent), while the majority of ongoing shortages of 
injectable generic oncology drugs that started prior to December 2010 and continued past 
the December 2010 deadline for this study were due to manufacturing problems, (9/15, 
60 percent). These products were dropped from the full analysis. 
Only 17 products (18 dosage forms as both cisplatin injection and powder 
qualified for the study) were available for full analysis. Of the 17 drugs remaining for 
analysis, 5/17 (29.4 percent) continued with brand name manufacturers as producers. For 
cisplatin, fluorouracil, and paclitaxel  (3/17, 17.6 percent); brand name products were 
discontinued the same year the shortage started (see Table 4). The brand version of three 
drugs (bleomycin, cyclophosphamide, and methotrexate) was discontinued after the first 
shortage began. Finally, the brand name of five drugs (29.4 percent) was discontinued at 





Trends in number of suppliers and reasons for shortage 
 




to first year of 
shortage 





                                         Shortages of injectable generic oncology drugs of interest (2002-2010) 
Fluorouracil  2003-2004 4 59 Supply/Demand 4 
 2004-2009 55 Unknown 3 
Methotrexate 2004-2008 55 55 Regulatory Problems 3 
Vinblastine 2002 -  
36 
Unknown Unknown 
 2005-2006 4 Manufacturing 2 
 2008-2010 32 Unknown 2 
Mitomycin  2008-2010 28 28 Manufacturing 4 
Epirubicin Hydrochloride* 2007-2008 17 17 Unknown 1 
Cisplatin      
             Injection  2005-2006 6 17 Manufacturing 3 
 2008-2009 8 Unknown 4 
             Powder 2005 3 Supply/Demand 5 
Doxorubicin Hydrochloride* 2001-2002 8 13 Manufacturing  Unknown 
 2008-2009 5 Unknown 4 
Leucovorin 2008-2009 12 12 Manufacturing 2 
Bleomycin 2005-2006 2 9 Unknown 4 
 2007 7 Unknown 4 
Vincristine  2005-2006 9 9 Manufacturing 2 
Daunorubicin  Hydrochloride*  2010 8 8 Manufacturing 3 
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Table 6 continued 
Paclitaxel 2009 1 5 Unknown 7 
 2010 4  Unknown 8 
Cyclophosphamide 2004 1  
5 
Unknown 2 
     
 2005-2006 1 Unknown 2 
 2008 3 Discontinued 2 
Thiotepa  2008-2009 3 3 Manufacturing 2 
Ifosfamide* 2005-2006 3 3 Manufacturing 2 
Dacarbazine 2005-2006 2 2 Supply/Demand 5 
Pentostatin* 2010 2 2 Unknown 2 
Ongoing shortages of injectable generic oncology drugs (Shortages Prior to December 2010)** 
Cytarabine May 2008-April 2012  48 48 Supply/Demand 4 
Etoposide Dec. 2008-April 2012  41 41 Unknown 4 
Mitoxantrone Nov.2009-April 2012 30 30 Unknown 7 
Cisplatin inj. Feb. 2010-April 2012 27 27 Unknown 3 
Carboplatin May 2010-April 2012 24 24 Manufacturing 9 
Doxorubicin Hydrochloride May 2010-April 2012 24 24 Manufacturing 4 
Fludarabine May 2010-April 2012 24 24 Manufacturing 5 
Fluorouracil  July 2010-April 2012 24 24 Unknown 4 
Leucovorin May 2010-April 2012 24 24 Manufacturing 2 
Mesna May 2010-April 2012 24 24 Manufacturing 5 
Vincristine  May 2010-April 2012 24 24 Manufacturing 2 
Dacarbazine June 2010- April 
2012 
23 23 Manufacturing 5 
Idarubicin June 2010-April 2012 23 23 Manufacturing 4 
Methotrexate Nov. 2010-April 
2012 
18 18 Unknown 4 
Epirubicin Hydrochloride 2010-2011  15 15 Manufacturing 7 
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Table 6 continued 
 
* Brand name available as of December 2010 
** Active shortages were unresolved as of April 30, 2012 due to the time period of data collection (March-April 2012), but time was 
calculated based on a data collection end date of April 2012 
Ongoing shortages of injectable generic oncology drugs (Shortages After December 2010)** 
Irinotecan  Feb. 2011-April 
2012  
15 15 Unknown 10 
Thiotepa  Feb. 2011-April 
2012  
15 15 Unknown 2 
Daunorubicin Hydrochloride  March 2011-April 
2012 
14 14 Manufacturing  3 
Vinorelbine  March 2011-April 
2012  
14 14 Unknown 6 
Mitomycin  April 2011-April 
2012  
13 13 Unknown 3 
Paclitaxel May 2011-April 
2012 
12 12 Unknown 6 
Pentostatin 2011  2 7 Unknown 2 
 Dec. 2011-April 
2012 
5 Manufacturing 2 
Floxuridine  Nov. 2011-April 
2012 
6 6 Manufacturing  3 
Ifosfamide Lyophilized powder Nov. 2011-April 
2012 
6 6 Manufacturing 3 




6 6 Manufacturing 3 
Cyclophosphamide 2011  2 2 Manufacturing 2 
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Use of Supplier Trends as a Shortage Predictor 
 
To clearly demonstrate the volatility of the key manufacturers, Table 7 
summarizes the number of drugs that experienced shortages (2002-2010), and the average 
total months of shortages for drugs that still have a brand manufacturer, and drugs that no 
longer have a brand manufacturer (2002-2010). At the end of the observation period, five 
drugs out of the 17 drugs of interest still have the brand manufacturers in the market with 
an average of 8.6 ± 6.4 S.D months of shortages. On the other hand, the brand 
manufacturers discontinued 12 drugs (13 dosage form; as both cisplatin powder and 
injection were discontinued). Those 12 drugs had an average of 18.5 ± 19.8 S.D months 
of shortages. The volatility in the group where the brand was discontinued was higher 
than the group where the brand was still available.  
 
 
Use of Price Variation as a Shortage Predictor 
 
 Prices of the original 24 drugs of interest were collected from The Red Book 
(2002-2010). The decision then was not to proceed with collecting or analyzing data 
related to drug prices for the following reasons. First, the Red Book used to collect the 
data related to the AWP and the number of companies manufacturing the drugs was 
published at the beginning of each year. This has some implications such as; it does not 
represent the actual number of manufacturers in the market. Companies may enter or 
leave the market during the year without being documented in the Red Book. Second, the 
Red Book is not sensitive to changes in prices; it only publishes a benchmark price. 





Table 7: Volatility of 17 drugs of interest (2002-2010)  
Name of drug Total Shortage period (months) Reasons for 
Shortages 
 Volatility of five drugs that still have brand name manufacturer 
Epirubicin Hydrochloride 17 Unknown 
Doxorubicin Hydrochloride 13 Manufacturing 
Daunorubicin Hydrochloride 8 Manufacturing  
Ifosfamide 3 Manufacturing 
Pentostatin 2 Unknown  
Average ± S.D 8.6 ± 6.4  
Volatility of 12 drugs that were discontinued by the brand manufacturer 
Fluorouracil 59 Unknown + Supply/Demand 
Methotrexate 55 Regulatory Problems 
Vinblastine 36 Unknown + Manufacturing 
Mitomycin  28 Manufacturing  
Cisplatin injection  14 Unknown + Manufacturing 
Leucovorin 12 Manufacturing  
Bleomycin 9 Unknown  
Vincristine  9 Manufacturing  
Cyclophosphamide 5 Unknown + Discontinued 
Paclitaxel 5 Unknown  
Cisplatin powder 3 Supply/Demand 
Thiotepa  3 Manufacturing  
Dacarbazine 2 Supply/Demand 
Average ± S.D 18.5 ± 19.8  
 











Of the original 24 shortage drugs identified for more in-depth analysis, only 17 
drugs (18 dosage forms) remained as listed in Table 8.   
 
Supplier Fluctuation Trends as a Shortage Predictor 
 
Study findings suggested that the volatility of drug shortages is not in the number 
of suppliers prior to shortages, as some drugs had few suppliers (2, 3, or 4 suppliers) and 
others had so many suppliers (7, 9, or 10 suppliers). Rather the absence of the key 
manufacturer is associated with the discontinuation of the brand name, as shown in the 
case of cisplatin, fluorouracil, and paclitaxel.  So, the volatility is not in the number of 
manufacturers, but the key manufacturers themselves. This finding, which is specific to 
oncology drugs, is contrary to what was found in the IMS IHI study in 2011 where they 
 




Cyclophosphamide Mitomycin  
Dacarbazine Paclitaxel 
Daunorubicin  Hydrochloride  Pentostatin 
Doxorubicin Hydrochloride Thiotepa  
Epirubicin Hydrochloride Vinblastine 






showed that drugs that are supplied by three or fewer companies are at the highest risk of 
being in shortages regardless of the presence or absence of the brand manufacturer.50 
Another interpretation is that as we showed earlier, 80 percent of the oncology 
packages and vials sold in the US market were held by the top five generic injectable 
manufacturers.21 For that, efforts should be directed at approving generic products from 
manufacturers committed to providing stability in the marketplace, toward generic 
companies to make quality a priority, toward suppliers to have facilities and resources 
available for continued production. 
 
 
Use of Supplier Trends as a Shortage Predictor  
 
Another important interpretation from the results of this study is that the 
discontinuation of the brand names of the drugs was associated with a longer shortages 
period compared to shortages due manufacturing problems or delays as shown in Table 7. 
This is not matching to what was found by the GAO study in 2011.50 The GAO study 
showed that the average shortage lasted more than nine months, whereas in this study, the 
average shortages lasted 8.6 ± 6.4 and 18.5 ± 19.8 for drugs that brand name were still 
available and for drugs that the brand name manufacturers were discontinued. In reality, 
brand manufacturers may leave the market at any time after the patent expires and there 
is no way to force them to stay in the market.  
One of the limitations for this study is that it ended up with a small sample size 
(n=17) out of the original 24 drugs that were described in Chapter 3 (Table 2). Therefore, 
results and discussion were mainly focused on the remaining 17 drugs. Of the drugs that 
were excluded, some were excluded because the drug only had one manufacturer in the 
40 
 
studied period, such as oxaliplatin and dactinomycin. Others were excluded because not 
enough information on the shortages was available, because they experienced shortages 
after the cutoff date (December 2010) such as floxuridine and irinotecan, or the shortages 
started prior to December 2010, but were still active as of April 2012. Another limitation 
for this study is the dynamic marketplace. Information related to drug shortages changes 
quickly; there is always new information; drugs entered the shortage lists, others leave, 
new efforts, acts, law and so on. I had to choose a cutoff point where I am not going to 
update my paper anymore. 
Drug shortages are a topic of great interest to hospitals, pharmacists, providers, 
policy makers, and regulations bodies such as the FDA and the ASHP. Opportunities for 
future research are great. Future research on a bigger sample size and for a longer period 
of time may reveal more significant findings and predict trends that were not so clear or 
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